To our knowledge, our study provides the first experimental evidence that an alkyl lipid may act as a modifier of the response to anti-EGFR mAbs in colorectal cancer cells: an alkyl-lipid can overcome their primary tumor resistance, where mAbs single treatment fails to inhibit PI3K/Akt intracellular signaling. The gene discussed is PIK3CA; the disease is neoplasm.